Speaker Profile
M.D., MD, MS, FRCS(C), FACS, CMO, Oncobrain; and Assistant Chief of Surgical Services Senior Member, Department of GU Oncology Medical Director, Virtual Care Moffitt Cancer Center,
Biography
An internationally recognized urologic oncologist, academic surgeon, and healthcare innovator specializing in complex and rare genitourinary malignancies. A senior faculty at Moffitt Cancer Center, where he serves as Medical Director of Virtual Care advancing innovation focused care delivery, multidisciplinary oncology models, and second-opinion services. Dr. Spiess completed advanced surgical and oncologic training at McGill University and University of Texas MD Anderson Cancer Center, respectively and holds formal certification in Artificial Intelligence from Oxford University, with ongoing advanced AI leadership training.He has authored over 520 peer-reviewed publications with an H-index exceeding 50, and has received multiple academic and teaching awards including being the 2025 Moffitt Physician of the Year. Dr. Spiess holds prominent national and international leadership roles for the NCCN, ASCO, AUA, EAU, and ESMO. He also serves as Chief Medical Officer of OncoBrain AI, where he helps lead clinical strategy for AI-driven oncology education and decision-support platforms.
Talk
From Hours to Minutes: Rethinking Clinical Support in Oncology
Oncobrain helps oncologists move through complex decisions with clarity. It consumes and interprets data like an expert and grounds every recommendation in NCCNASCO guidelines with transparent reasoning, citations, and accuracy scoring. Designed to reduce cognitive load, it supports clinical judgment, surfaces helpful questions, offers optional specialist review, and strengthens confidence in decisions.
AI for Clinical Decision Support Systems Showcase:
Oncobrain
Oncobrain is an oncology-specific clinical reasoning engine that delivers optimal, guideline-concordant, patient-specific insights and treatment plans at the point of care. Built on data from over 1M patients, 2400 data points per oncology case and coupled with NCCN and ASCO guidelines, it turns complex data into clear, actionable recommendations that reduce variation, support clinicians, and improve treatment planning and quality.
Session Abstract – PMWC 2026 Silicon Valley
"The PMWC 2026 AI for Clinical Decision Support Showcase will provide a 15-30 minute time slot for selected organizations, including commercial companies, clinical testing labs, and medical research institutions, to present their latest advancements, insights, applications, and technologies to an audience of clinicians, leading investigators, academic institutions, pharma and biotech, investors, and potential clients. We will learn about new technologies and findings that promise expedited, cost-effective, and accurate clinical diagnosis for early disease detection, treatment decisions, and disease prevention.
- Clinical Dx/Oncology (including Liquid Biopsy)
- Clinical Dx/Cardio Vascular
- Clinical Dx/Neurodegenerative
